Edgewise (EWTX) CMO Joanne M. Donovan Sells ~9,441 Shares

What Happened
Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), exercised convertible/derivative awards (12,812 shares reported) and sold shares in the open market on August 12–13, 2026. She disposed of a total of 9,441 shares in multiple transactions for aggregate proceeds of about $412,704 (sales ranged roughly $43.12–$44.57 per share). The filing also reports grants of 32,500 and 65,000 restricted stock units (RSUs) granted for no cash consideration (total 97,500 RSUs) that vest in scheduled installments.

Key Details

• Transaction dates: primary activity on Aug 12, 2026 (and one sale on Aug 13, 2026). Form filed Aug 14, 2026 (within standard Form 4 timing).
• Sales: 2,839; 2,779; 104; 800; and 2,919 shares sold — total 9,441 shares for ~$412,704. Reported prices are averages; detailed price ranges listed in footnotes (approx. $43.12–$44.57).
• Exercises/Conversions: two derivative exercise entries totaling 12,812 shares acquired at $0 reported (these relate to option/derivative conversions). Two matching derivative-disposition entries are reported at $0.
• Grants: 32,500 RSUs (vesting in four equal annual installments beginning Aug 12, 2026) and 65,000 RSUs (vesting in four equal annual installments beginning Aug 12, 2027).
• Tax/plan notes: Some sales represent "sell-to-cover" for statutory tax withholding (not discretionary sales). Several sales were effected under a Rule 10b5-1 trading plan adopted Dec 26, 2025.
• Shares owned after the transactions: not provided in the excerpt of the filing.

Context

• The sequence (exercise/conversion followed by sales and zero-dollar derivative disposals) is consistent with exercising option-like awards and immediately selling shares to cover taxes or to monetize exercised shares (i.e., effectively a cashless/partial sale).
• RSU grants are awards that vest over time and do not immediately indicate a buy/sell view by the executive.
• These filings are factual disclosures of insider activity; they do not by themselves prove a change in the executive’s view of the company.